30 results about "Group B beta-hemolytic streptococci" patented technology

The invention belongs to the medical technical field and discloses the application of high-purity in the preparation of antibacterial medicine, antiviral medicine and other medicines. The invention proves the antipyretic, anti-inflammation, immunity enhancement, antibacterial and anti-virus effects of high-purity forsythiaside through the following experiments: (1) the experiment that high-purityforsythiaside has antipyretic effect on fever rats; (2) the experiment that high-purity forsythiaside inhibits xylene-induced mice ear edema, xylene-reduced capillary permeability of mice; (3) the experiment that high-purity forsythiaside increases carbon clearance ability of mice and increases the lymphocyte transformation rate; (4) the experiment that high-purity forsythiaside has vitro anti-influenza A type virus effect and in-vivo anti-respiratory syncytial virus effect; (5) the experiment that high-purity forsythiaside has vitro inhibition effects on beta-hemolytic streptococcus, staphylococcus aureus, streptococcus viridans and staphylococcus epidermidis.

This invention relates to Ligulatrovine A separated from Ligularia actroviolacea that can prevent and treat diseases related to Staphylococcus aureus and beta hemolytic streptococcus, its pharmaceutical salts and drug composition. Ligulatrovine A has significant inhibitive effect on Gram-positive bacteria, and can prevent and treat diseases such as boil, pustule, pneumonia, osteomyelitis, acute myocarditis, endocarditis, meningitis, mastitis, cystitis, pelvic inflammation, urinary inflammation, prostatitis, bacteremia, or abscess in muscle, skin, urogential region or central nervous system caused by Gram-positive bacteria infection.

The present invention relates to flavonoid glycosides isolated from dandelion and capable of preventing and treating Staphylococcus aureus and beta-hemolytic streptococcus infection diseases and their pharmaceutically acceptable salts, their anti-infective medicinal uses, and pharmaceutical compositions containing these compounds. The two novel flavonoid glycoside compounds of the present invention have obvious effects of inhibiting the growth of Staphylococcus aureus and beta-hemolytic streptococcus, and can be expected to be used for the prevention and treatment of boils, pustules and toxic epidermal decomposition caused by the infection of these two. , pneumonia, osteomyelitis, acute myocarditis, endocarditis, meningitis, mastitis, cystitis, pelvic inflammatory disease, urinary tract inflammation, prostatitis, bacteremia, toxic shock syndrome, lymphadenitis, arthritis, pharyngitis , cervicitis, and muscle, skin, urogenital tract, central nervous system abscesses.

The invention discloses a traditional Chinese medicine preparation for clearing throat, which is prepared from the following raw materials in parts by weight: 1-5 parts of Radix Radix Radix, 1-5 parts of Radix Radix Radix, 1-5 parts of Didantou and 1-5 parts of Licorice. The throat-clearing traditional Chinese medicine preparation has good effects on treating influenza, upper respiratory tract infection, tonsillitis, pharyngitis and the like. According to the in vitro antibacterial experiment, Qinghoukou buccal tablets have a certain inhibitory and killing effect on Staphylococcus aureus, A-hemolytic streptococcus, B-hemolytic streptococcus, Streptococcus pneumoniae and Haemophilus influenzae; Antibacterial experiments in vivo proved that Qinghoukou buccal tablets had a certain protective effect on the death of mice caused by intraperitoneal injection of Staphylococcus aureus. Its antibacterial efficacy in vivo and in vitro provides a theoretical basis for clinical application. The traditional Chinese medicine preparation is based on classification, has strong pertinence, is combined with oral administration and local external application, and has definite curative effect.